IRIS
BARCHIESI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.204
EU - Europa 4.537
AS - Asia 4.312
SA - Sud America 1.217
AF - Africa 243
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 4
Totale 19.524
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.055
SG - Singapore 1.304
VN - Vietnam 1.005
BR - Brasile 924
RU - Federazione Russa 797
UA - Ucraina 788
CN - Cina 531
IT - Italia 484
DE - Germania 466
IE - Irlanda 461
TR - Turchia 457
SE - Svezia 382
HK - Hong Kong 344
FR - Francia 292
DK - Danimarca 283
FI - Finlandia 213
GB - Regno Unito 197
KR - Corea 157
AR - Argentina 109
IN - India 100
CI - Costa d'Avorio 95
BD - Bangladesh 63
MX - Messico 62
CA - Canada 60
EC - Ecuador 49
ZA - Sudafrica 49
ID - Indonesia 48
IQ - Iraq 42
NL - Olanda 39
CO - Colombia 35
JP - Giappone 27
PK - Pakistan 27
PL - Polonia 27
PY - Paraguay 26
CL - Cile 25
MA - Marocco 25
IR - Iran 24
AT - Austria 22
PH - Filippine 21
VE - Venezuela 21
UZ - Uzbekistan 20
ES - Italia 17
SA - Arabia Saudita 16
BE - Belgio 15
AZ - Azerbaigian 13
EG - Egitto 13
TN - Tunisia 13
MY - Malesia 12
PE - Perù 12
KZ - Kazakistan 11
KE - Kenya 10
NP - Nepal 10
UY - Uruguay 10
JO - Giordania 9
TH - Thailandia 9
BA - Bosnia-Erzegovina 8
DZ - Algeria 8
IL - Israele 7
KW - Kuwait 7
ET - Etiopia 6
EU - Europa 6
LB - Libano 6
AE - Emirati Arabi Uniti 5
AL - Albania 5
DO - Repubblica Dominicana 5
HN - Honduras 5
LT - Lituania 5
MD - Moldavia 5
PS - Palestinian Territory 5
AO - Angola 4
AU - Australia 4
BH - Bahrain 4
BO - Bolivia 4
BY - Bielorussia 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
JM - Giamaica 4
KG - Kirghizistan 4
NG - Nigeria 4
PA - Panama 4
SY - Repubblica araba siriana 4
AM - Armenia 3
CM - Camerun 3
HR - Croazia 3
NO - Norvegia 3
OM - Oman 3
PT - Portogallo 3
SN - Senegal 3
TW - Taiwan 3
BG - Bulgaria 2
CH - Svizzera 2
GE - Georgia 2
GY - Guiana 2
LK - Sri Lanka 2
MU - Mauritius 2
QA - Qatar 2
RO - Romania 2
RS - Serbia 2
TT - Trinidad e Tobago 2
A1 - Anonimo 1
Totale 19.502
Salva come PNG Salva come JPEG
Città #
Ashburn 1.402
Singapore 842
Jacksonville 794
Fairfield 742
Dallas 634
Chandler 537
Dublin 455
Boardman 422
Ho Chi Minh City 323
Hong Kong 321
Wilmington 315
Woodbridge 303
Seattle 256
Houston 250
Des Moines 243
Cambridge 241
New York 241
San Jose 232
Hanoi 224
The Dalles 200
Ann Arbor 193
Lawrence 173
Princeton 173
San Mateo 172
Lauterbourg 151
Moscow 142
Los Angeles 118
Beijing 117
Turin 103
San Diego 98
Abidjan 95
Hefei 88
Munich 87
São Paulo 76
Da Nang 64
Council Bluffs 63
Centro 51
Buffalo 49
Haiphong 44
Chicago 41
Redmond 41
Helsinki 40
London 40
Rio de Janeiro 32
Nuremberg 31
Ancona 27
Santa Clara 26
Turku 26
Shanghai 25
Brooklyn 24
Tokyo 24
Columbus 22
Frankfurt am Main 22
Johannesburg 22
Biên Hòa 21
Montreal 21
Orem 20
Warsaw 20
Milan 19
Tashkent 19
Norwalk 18
Washington 18
Baghdad 17
Chennai 17
Dhaka 17
Guangzhou 17
Guayaquil 17
Belo Horizonte 16
Marche 16
Mexico City 16
Ninh Bình 16
Ottawa 16
Pune 16
Brasília 15
Nha Trang 15
Quito 15
Amsterdam 14
Brussels 14
Curitiba 14
Porto Alegre 14
Ankara 13
Atlanta 13
Boston 13
Hải Dương 13
Kilburn 13
Salt Lake City 13
Stockholm 13
Cape Town 12
Wuhan 12
Asunción 11
Baku 11
Bologna 11
Manchester 11
Mumbai 11
Poplar 11
Rome 11
Campinas 10
Caracas 10
Denver 10
Fortaleza 10
Totale 12.147
Salva come PNG Salva come JPEG
Nome #
Antimicrobial Resistance: A Challenge for the Future 298
Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. 204
An (Italian) proposal for a comprehensive approach to infections across the surgical pathway 196
ACTIVITY OF THE NEW ANTIFUNGAL TRIAZOLE, POSACONAZOLE, AGAINST CRYPTOCOCCUS NEOFORMANS 185
Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture. 182
Candida guilliermondii fungemia in patients with hematologic malignancies. 181
Antimicrobial activity of polycationic peptides 178
Invasive Aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases 177
Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients 172
Epidemiology and outcome of systemic infections due to saprochaete capitata: case report and review of the literature 168
Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection 160
Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. 158
Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study 157
Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study 154
Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014 153
Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards 152
Characterisation of candidemia in patients with recent surgery: A 7-year experience 149
Epidemiology and microbiology of surgical wound infections. 147
Aspergillus spp invasive external otitis: favourable outcome with a medical approach 146
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 145
Acute histoplasmosis in immunocompetent travelers: a systematic review of literature 145
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. 145
Species distribution and antifungal susceptibilities of bloodstream Candida isolates: a nine-years single center survey 145
Analysis of antibody response to Cryptococcus neoformans in five patients with AIDS and cryptococcosis by immunoblotting. 143
Anticryptosporidial activity of ranalexin, lasalocid and azithromycin alone and in combination in cell lines. 143
Candidemia in the elderly: What does it change? 143
In-vitro effect of short-term exposure to two synthetic peptides, alone or in combination with clarithromycin or rifabutin, on Cryptosporidium parvum infectivity. 142
Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes 142
Comparison of liver fibrosis progression in HIV/HCV co-infected and HCV mono-infected patients by transient elastometry 141
Prevalence and predictors of malignancies in a polycentric cohort of HIV patients from Italy 139
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU 139
Factors related to outcome of bloodstream infections due to Candida parapsilosis complex 137
Trichosporon beigelii fungaemia in an AIDS patient. 136
Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection. 136
In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp. 133
Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals 133
High rate of ceftobiprole resistance among clinical methicillin-resistant Staphylococcus aureus isolates from a hospital in central Italy 133
Candidemia in Internal Medicine: Facing the New Challenge 131
Comparison of three methods for testing azole susceptibilities of Candida albicans strains isolated sequentially from the oral cavities of aids patients. 130
Anticryptosporidial activity of cationic peptides alone and in combination with inhibitors of ion transport systems. 129
Clinical and epidemiological characteristics of KPC-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy 128
Heterozygosis and pathogenicity of Cryptococcus neoformans AD-hybrid isolates. 127
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). 126
Osteomyelitis caused by Aspergillusspecies: a review of 310 reported cases 126
Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report. 123
Sequential therapy with caspofungin and fluconazole for Candida albicans infection. 122
A comparative analysis of unintegrated HIV-1 DNA measurement as a potential biomarker of the cellular reservoir in the blood of patients controlling and non-controlling viral replication 122
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. 121
Antifungal susceptibility patterns of yeast isolates causing bloodstream infections. 119
Antifungal Combinations against Candida Species: From Bench to Bedside 118
Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis. 118
Central venous catheter unrelated candidemia influences the outcome of infection in patients with solid tumors 118
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. 117
EUCAST technical note on posaconazole. 117
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 117
Antifungal combinations in dermatophytes 117
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. 115
Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. 115
Genotypic and phenotypic characteristics of Candida parapsilosis bloodstream isolates: Health Care Associated Infections in a teaching Hospital in Italy 113
In-vitro activity of rifabutin and albendazolo singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. 113
Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi. 111
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. 111
Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. 111
In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes 111
Reply to Ma et al.: Osteomyelitis caused by aspergillus species 111
Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin. 110
In vitro activities of voriconazole in combination with other three antifungal agents against Candida glabrata 109
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. 109
Infection due to Absidia corymbifera in a patient with a massive crush trauma of the foot 109
EUCAST Technical Note on voriconazole. 109
Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata 108
In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. 108
Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. 108
How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates 108
Prevalence and predictors of malignancies in HIV patients: results of a retrospective multicentric Italian cohort. 108
In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. 107
Voriconazole and multidrug resistance in Candida albicans. 107
In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. 107
Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches 107
In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes. 106
Tolerance to amphotericin B in clinical isolates of Candida tropicalis. 106
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. 106
Antiretroviral therapy management and rationalisation of available resources 105
Interactions of Posaconazole and Flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 103
Molecular epidemiology of Italian clinical Cryptococcus neoformans var. grubii isolates 103
Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report. 103
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. 102
Electrophoretic karyotyping and antifungal susceptibility patterns of Candida parapsilosis clinical isolates causing deep and superficial fungal infections 102
The Clinical Characteristics of Bloodstream Infections Due to Candida spp. in Patients Hospitalized in Intensive Care Units during the SARS-CoV-2 Pandemic: The Results of a Multicenter Study 101
Epidemiology of onychomycosis and paronychia in the area of ANCONA (ITALY) over a period of 5 years 101
Comparison of four methods for DNA typing of clinical isolates of Candida glabrata. 101
Caspofungin in combination with amphotericin B against Candida parapsilosis. 101
In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes. 101
EUCAST technical note on Amphotericin B 101
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. 101
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. 101
In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans. 100
In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. 99
In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. 99
EUCAST technical note on fluconazole. 99
Totale 12.829
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.911
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.911
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021680 0 0 0 0 0 0 0 0 0 283 289 108
2021/20221.519 133 433 13 42 20 63 117 70 76 136 156 260
2022/20232.071 215 172 150 113 135 354 13 96 563 11 176 73
2023/20241.297 214 25 68 240 248 280 26 18 15 14 15 134
2024/20252.350 212 203 166 29 61 60 168 112 609 161 238 331
2025/20267.423 414 589 765 1.144 668 404 1.388 762 708 581 0 0
Totale 19.759